Related by context. All words. (Click for frequent words.) 64 subjects 55 Topics 53 Participants 52 Patients 51 Secondary endpoints 50 n = 48 Efficacy endpoints 47 Somnolence 46 Primary endpoints 46 Secondary efficacy endpoints 46 THIS STUDY 45 Students 45 Individuals 45 male Wistar rats 45 ≤ 45 subscales 45 subscale scores 45 Subgroups 44 overnight polysomnography 44 Respondents 44 p = #.# [002] 44 Variables 44 ≥ 44 randomized #:#:# 44 concomitant medications 44 point Likert scale 44 randomized 44 Exclusion criteria 43 premorbid 43 Brief Psychiatric 43 Topics covered 43 Endpoints 43 topics 43 Female Sexual Function 43 Main Outcome Measures 43 randomized #:# 43 Pain Intensity 43 pharmacokinetics PK 43 Symptom severity 43 secondary endpoints 43 WOMAC pain 43 #.#/#.# mm Hg [002] 43 bivariate analyzes 43 posttreatment 42 HRQL 42 Dosages 42 subscore 42 Cognitive Function 42 verbal fluency 42 #:# randomization 42 Subsets 42 oral hypoglycemic 42 TDF FTC 42 Methods 42 Correlates 42 nulliparous women 42 Prerequisites 42 Applicants 42 secondary efficacy endpoints 42 histologically proven 42 Randomized controlled 42 Fasting plasma glucose 41 Visual Analog Scale 41 Categories 41 FOLPI 41 Adolescents 41 fasting insulin 41 p = 41 EQ 5D 41 randomly assigned 41 sociodemographic variables 41 CONCERTA ® 41 multiple logistic regression 41 evaluable 41 participants 41 timepoint 41 Patient Populations 41 mg BID 41 Baseline characteristics 41 odds ratios ORs 41 linear regression models 41 Outcomes Study 41 mg Pycnogenol 41 umol L 41 normotensive 41 Main Outcome Measure 41 subtests 41 preoperative 41 Generalized Anxiety Disorder 41 systolic BP 41 efavirenz EFV 41 Depressive Symptoms 41 pharmacodynamic parameters 41 aminotransferase levels 41 HAM D# 41 Functional Outcomes 40 nasopharyngitis headache 40 psychopathological symptoms 40 flutamide 40 DAS# scores 40 Placebo Controlled Study 40 primary endpoints 40 Themes 40 Examples 40 timepoints 40 placebo 40 suicide attempters 40 male Sprague Dawley 40 Global Impression 40 Epworth Sleepiness Scale 40 Key secondary endpoints 40 ascending doses 40 Watchful Waiting 40 Postoperative 40 prospectively randomized 40 subcutaneous dose 40 logistic regression model 40 covariate 40 Genotypes 40 #mg QD [001] 40 salivary cortisol 40 mcg linaclotide 40 insulin detemir 40 Successful applicants 40 Index FSFI 40 dose proportionality 40 treatment emergent adverse 40 REYATAZ r arm 40 Cognitive Functioning 40 Thrombolysis 40 Mice 40 Efficacy 40 Subgroup analyzes 40 cognitive domains 40 psychoeducation 40 glucose intolerant 40 Exercisers 40 FACIT 40 genotypic resistance 40 FDG PET scans 40 spirometric 40 Kidney Function 40 Sociodemographic 40 postintervention 40 sociodemographic characteristics 40 nighttime awakenings 40 #mg BID [002] 40 APTIVUS r 40 Comorbidities 40 WARNINGS Myopathy Rhabdomyolysis 40 YMRS 40 HbA 1c levels 40 p = #.# [004] 40 Estrogen Alone 39 symptom severity 39 interquartile range 39 Long Term Effects 39 Subtypes 39 ANCOVA 39 randomization 39 CAMMS# 39 Issues 39 IPSS 39 sonographic examinations 39 Erectile Function IIEF 39 Bronchodilator 39 healthy unmedicated 39 Likert 39 Neonates 39 Psoriasis Area 39 Postmarketing 39 Intervention Trial 39 hematologic parameters 39 hypogonadal men 39 cytoreductive nephrectomy 39 Index CDAI 39 % CI #.#-#.# [003] 39 ascending dose 39 Complication rates 39 semistructured interview 39 subcutaneous doses 39 MMSE score 39 preoperatively 39 inhaled tobramycin 39 postoperatively 39 Secondary endpoints include 39 Dose limiting toxicities 39 Types 39 MMSE scores 39 Attendees 39 tertiles 39 serum leptin 39 Secondary endpoints included 39 DSM IV Axis 39 nonrandomized 39 saline placebo 39 mg kg dose 39 Wistar rats 39 univariate analyzes 39 Courses 39 GnRH agonist 39 pharmacokinetic parameters 39 anthropometric measurements 39 exploratory endpoints 39 mg d 39 NIH CPSI 39 randomized crossover 39 Patients Receiving 39 risperidone olanzapine 39 clinically meaningful improvements 39 Polyp Prevention Trial 39 baseline A1C 39 events TEAEs 39 hypersomnia 39 Suboptimal 39 Capacity FVC 39 euthymic 39 didactic lectures 39 dosage regimens 39 Neuropsychiatric Inventory NPI 39 QD dosing 39 Toxicities 39 posttest 39 Adults 39 dietary questionnaires 39 μg kg 39 Modifiable 39 potential confounders 39 RRMS patients 39 mcg QD 39 Pharmacodynamics 39 acute subacute 39 BMI z 39 Urogenital Distress Inventory 39 Scale Cognitive Subscale 39 meta regression 39 relapsed MM 39 P = .# 39 Raloxifene Evaluation MORE 39 divalproex sodium 39 mg q#h 39 erection hardness 38 Treatment Outcome 38 hyperlipidemic 38 Aspects 38 mg orally 38 Randomized 38 HCV Genotype 38 ADAS Cog 38 syndromal 38 primary efficacy endpoints 38 baseline LDH 38 Subjective 38 polysomnographic 38 Protease Inhibitors 38 aspartate aminotransferase AST 38 Diagnostic Criteria 38 antiretroviral naive 38 IIEF 38 Patients Treated With 38 prospective randomized multicenter 38 somatoform disorders 38 HBeAg positive 38 Trainees 38 intratympanic 38 parkinsonian 38 ENGAGE AF TIMI 38 Eligibility criteria 38 intraocular inflammation 38 subscores 38 Persons 38 #mg QD [002] 38 MVax R 38 Chronic Constipation 38 Pharmacokinetic 38 Rating Scale MADRS 38 hours postdose 38 undergoing peritoneal dialysis 38 nausea somnolence 38 WHEL 38 nonobese 38 microgram kg 38 Depressive symptoms 38 INFERGEN 38 esophageal reflux 38 METHODS 38 intramuscularly 38 Outcome Measures 38 Suicidal Ideation 38 interrater 38 elevated transaminases 38 Randomized Controlled Trials 38 Psychodynamic 38 Responses 38 Prerequisite 38 placebo controlled dose escalation 38 nonresponders 38 cells uL 38 Sustained Efficacy 38 PANSS 38 intravenous tPA 38 Incontinence Impact Questionnaire 38 Likert scale 38 lacosamide 38 treatment emergent AEs 38 reflux symptoms 38 affective disorders 38 Montgomery Asberg Depression 38 MAS XR 38 Sprague Dawley rats 38 F FDG 38 diastolic BP 38 antiretroviral naïve 38 neurocognitive function 38 SAEs 38 Adverse effects 38 melphalan prednisone 38 SGRQ 38 laboratory abnormalities 38 Scale PANSS 38 Behaviours 38 Commonly 38 sociodemographics 38 Items 38 depressive symptom 38 Cognitive Dysfunction 38 ABC/3TC 38 Gender Sexuality 38 RECIST Response Evaluation Criteria 38 PREZISTA ritonavir 38 CDAI 38 Symptoms 38 runny nose nasal congestion 38 Demonstrates Efficacy 38 sociodemographic factors 38 intercourses 38 QoL 38 generalized estimating 38 Surgical Procedures 38 progression TTP 38 Phase 2a Trial 38 atypical neuroleptics 38 % CI #.#-#.# [008] 38 dyads 38 Rigorously 38 EURIDIS 38 Acute Physiology 38 HRQoL 38 Coronary CTA 38 polytherapy 38 concurrent chemoradiation 38 evaluable subjects 38 Liraglutide Effect 38 antiepileptics 38 ALT flares 38 conjugated equine estrogen 38 Sleep Disturbances 38 events AEs 38 Glucose tolerance 38 chills fever headache 38 alicaforsen enema 38 anticholinergics 38 virologic breakthrough 38 telaprevir dosing 38 Erectile Function 38 Cognitive Impairment 37 UPDRS motor 37 VLBW 37 Stent Restenosis 37 hematological parameters 37 extensive metabolizers 37 interrater reliability 37 Erectile 37 headache abdominal pain 37 Responders 37 BMI ≥ 37 irregular menses 37 rizatriptan 37 INVEGA ® 37 â ‰ ¥ 37 Adverse events 37 Electives 37 prespecified 37 Atopic 37 Pharmacokinetics PK 37 symptomatology 37 p = .# [002] 37 fasting plasma 37 Global Impression CGI 37 headache nausea diarrhea 37 Hepatotoxicity 37 CI -#.# 37 Meta analyzes 37 Vildagliptin 37 MADRS 37 cluster randomized controlled 37 mg RDEA# 37 confidence interval CI 37 HBeAg negative patients 37 PLMs 37 Low Incidence 37 Psychological Distress 37 blinded randomized placebo controlled 37 Registrants 37 brachial artery flow 37 muscle biopsies 37 FDA defined valvulopathy 37 Urogenital 37 Pharmacodynamic 37 Adverse Effects 37 prospectively defined 37 randomisation 37 Distress Scale 37 Treatment Naive 37 Histological 37 follicular phase 37 prior chemotherapy regimens 37 leucopenia 37 Elective courses 37 PSQI 37 serum lipids 37 Sexual Satisfaction 37 postmenopausal osteoporotic women 37 Lipid Levels 37 PRECAUTIONS Drug Interactions 37 β blockers 37 paresthesias 37 PBMCs 37 Restless Legs 37 PRECiSE 37 Score DAS 37 Atherosclerotic 37 cold pressor 37 REYATAZ ® 37 Preoperatively 37 posttransplant 37 TMC# C# 37 Randomized Double Blind 37 ECOG PS 37 prospectively stratified 37 nausea photophobia 37 EDSS scores 37 Learning Experiences 37 ejaculatory function 37 tipranavir r 37 Teriflunomide 37 CIMZIA TM certolizumab pegol 37 ski lls 37 Excessive Sleepiness 37 SBP DBP 37 Fasting glucose 37 Prolongation 37 T1DM 37 ILLUSTRATE 37 hepatic function 37 concurrent ITP 37 Glatiramer Acetate 37 System IPSS 37 mg dosed 37 CPAP adherence 37 biochemical relapse 37 mITT population 37 DSM IV criteria 37 bivariate 37 Elderly Patients 37 psychiatric outpatients 37 4mg/kg 37 Assessment Questionnaire 37 elevated ALT 37 Multiple Ascending Dose 37 psychiatric inpatients 37 Visual Analogue Scale VAS 37 headache nasopharyngitis 37 preintervention 37 Countries 37 Blood Pressure Drugs 37 Partial Onset Seizures 37 covariates 37 HIV RNA 37 decrements 37 Showed Significant 37 abdominal pain flatulence 37 Sterilization Supplies Markets Independently 37 Suicidal Behavior 37 periprocedural 37 Cardiovascular Risk Factors 37 moderate hepatic impairment 37 atazanavir ritonavir 37 preservice teachers 37 intranasal dose 37 dose cohorts 37 SSRI citalopram 37 Personal Narratives 37 TEAEs 37 ß blockers 37 sublingual nitroglycerin 37 IRLS 37 TLUS 37 secondary endpoint 37 intra articular injection 37 Carotid Endarterectomy 37 demonstrated statistically significant 37 Colorectal Cancers 37 Teens 37 Personality Traits 37 Symptom 37 Predictors 37 Oral Insulin Capsule 37 placebo capsules 37 constipation dizziness 37 HbA1c levels 37 drug eluting stent implantation 37 multicentre prospective 37 maximal doses 37 prospective observational cohort 37 thienopyridines 37 hematological adverse 37 Sleep Patterns 37 Timed Walk 37 dose titration 37 inert placebo 37 irritability mood swings 37 LUTS 37 affective psychosis 37 nonfatal cardiac arrest 37 Structured Clinical 37 Montgomery Åsberg Depression 37 nonfasting 37 Non Responders 37 Evoked 37 Colorectal Cancer Patients 37 neurosensory 37 antiangiogenic therapy 37 Health Assessment Questionnaire 37 Univariate analysis 37 stage IIIB 37 Exacerbation 37 Genes Linked 37 dichotomized 37 pharmacokinetics 37 bortezomib refractory 37 tonsillar hypertrophy 37 blinded placebo 37 Late Breaker 37 Beta Blockers 37 Hypertensive Patients 36 MARINOL R 36 BEXXAR Therapeutic Regimen 36 Double Blind Randomized 36 Interviewees 36 Ischemic 36 #mg/day [001] 36 monoamine oxidase inhibitors MAOIs 36 baseline CD4 36 SSRI SNRI 36 irritability headaches 36 Immunomodulatory 36 neuropsychological tests 36 blind placebo 36 baseline HbA1c 36 Clinician Administered PTSD 36 MBq 36 Flu Cy 36 GLIADEL R Wafer 36 F FDG PET 36 phonophobia 36 Severity Index 36 depressive symptoms 36 Pediatric Patients 36 vitreous floaters 36 abdominal distension 36 mu opioid agonist analgesics 36 specific antigen PSA 36 subtest 36 Decitabine 36 Endarterectomy 36 chi ^ sup 36 dose cohort 36 treatment naïve genotype 36 International Prostate Symptom 36 prospective cohort 36 Strongly Disagree 36 neuroleptic 36 O PPDS 36 mg FV 36 Insulin sensitivity 36 univariate analysis 36 Hospitalized Patients 36 IBDQ 36 sensory gating 36 fluoxetine paroxetine 36 Statistically Significant 36 calcaneal fractures 36 Postmenopausal Women 36 pain catastrophizing 36 postdose 36 r = 36 Wechsler Adult 36 colesevelam 36 Sustained Virologic Response 36 beta blocker therapy 36 mean ± SEM 36 HAQ DI 36 Treated Patients 36 Placebo controlled 36 Brain Functions 36 isocaloric 36 Issues Relating 36 Arm Shoulder 36 physiology anatomy 36 amoxicillin clavulanate 36 sociodemographic 36 HAMD 36 Neuroticism 36 Research Diagnostic Criteria 36 comorbid conditions 36 Coursework 36 blinded placebo controlled 36 Shows Efficacy 36 Transesophageal 36 randomized controlled trials RCTs 36 Non Inferiority 36 PERMP 36 DLTs 36 bronchoalveolar lavage fluid 36 ST Segment Elevation 36 oral analgesics 36 placebo p = 36 Stem Cell Transplants 36 Traficet EN 36 adverse reactions ≥ 36 Postprandial 36 sUA 36 Coronary Artery Bypass Surgery 36 Cardiotoxicity 36 multivariate analyzes 36 Intracerebral 36 ng dl 36 dimensional ultrasonography 36 lipid lowering agents 36 #mg/m# [002] 36 Coronary Artery Calcium 36 differentially expressed genes 36 Contraindications 36 metabolite concentrations 36 hypoglycemic events 36 Subgroup Analysis 36 lopinavir r 36 trials RCTs 36 oral antidiabetes 36 inactive placebo 36 PANSS scores 36 Obstructive 36 PREZISTA r 36 schizophrenia schizoaffective disorder 36 hsCRP levels 36 #mg/kg [002] 36 blood Phe levels 36 Kaplan Meier curves 36 #mg/m# [001] 36 Novel Compound 36 newer antipsychotic medications 36 angiographically 36 adenotonsillectomy 36 doxorubicin cyclophosphamide 36 ± SEM 36 intima media thickness 36 Females 36 TYSABRI treated 36 serum concentrations 36 urinary bowel 36 ocular adverse 36 triacylglycerol concentrations 36 Postmenopausal 36 adjunctive placebo 36 Generalised Anxiety Disorder 36 postprocedure 36 MMSE 36 sedation somnolence 36 nonobese patients 36 #mg/day [002] 36 antidiabetic medications 36 Solid Tumors 36 GERD migraine headaches 36 CAVEATS 36 oral alendronate 36 Pupils 36 dose pharmacokinetic 36 schizotypal 36 Scale EDSS score 36 receiving highly emetogenic 36 Antiviral Activity 36 Subgroup analysis 36 Factors influencing 36 parietal cortices 36 Stressors 36 Rating Scale BPRS 36 ONGLYZA saxagliptin 36 intermittent dosing 36 Kidney Donors 36 Eligible applicants 36 prospective observational studies 36 intraperitoneal injection 36 premenopause 36 Requirements 36 Demonstrated Significant 36 Endothelial Function 36 wrist actigraphy 36 multicenter Phase III 36 chest radiographs 36 Alequel 36 Advanced Primary Squamous 36 Pooled Analysis 36 Treatment Regimens 36 dose regimens 36 RESIST studies 36 Infarct 36 Insulin Secretion 36 somnolence headache 36 % CI #.#-#.# [002] 36 amygdala activation 36 risk reducing salpingo 36 CI = 36 somatoform disorder 36 pretest 36 Inadequately 36 5mg/kg 36 psychosocial functioning 36 Lymphocyte 36 Schizophrenics 36 ug kg 36 Serious Adverse Event 36 nondiabetic subjects 36 Tiotropium 36 ADCS ADL 36 nonmetastatic 36 macroalbuminuria 36 tertile 36 virological failure 36 mg/m2 dose 36 Scintigraphy 36 neuroD2 36 State Examination MMSE 36 desvenlafaxine succinate 36 statistically significant improvement 36 fasting glucose 36 Phase 2b dose 36 BPS IC 36 certolizumab 36 Long Term Efficacy 36 hypocalcemia 36 eNO 36 evaluable patients 36 mild renal insufficiency 36 Campers 36 virologic responses 36 Geriatric Depression 36 VcMP 36 endoscopic remission 36 immunostaining 36 ritonavir boosted lopinavir 36 Investigational Agent 36 Hypertensive adverse reactions 36 lopinavir r arm 36 multicenter randomized controlled 36 epigastric pain 36 PANSS Positive 36 Aromatase Inhibitors 36 DRD2 36 infliximab therapy 36 prodromal symptoms 36 Ejection Fraction 36 Brain Scans 36 Pre Marital 36 Genetic Markers 36 Beneficiaries 36 clinically meaningful improvement 36 extrapyramidal symptoms 36 dose escalation phase 36 cerebral infarctions 36 IQR 36 cynomolgus macaques 36 adolescent females 36 Withdrawal symptoms 36 Others 36 Serum concentrations 36 elevated creatinine 36 cognitive affective 36 glucose insulin 36 Dissertations 36 Symptom Scale 36 maximal treadmill 36 citalopram 36 sd = 36 efficacy endpoints 36 Hematologic 36 hippocampal volumes 36 experimental allergic encephalomyelitis 36 Neuroprotective Effects 36 Inpatients 36 Dose Reduction 36 Triglyceride levels 36 visceral metastases 36 fasting plasma glucose FPG 36 Likert Scale 36 rCBF 36 Macular Edema 36 Logistic regression analysis 36 Gestational 36 Antiviral Therapy 36 HRQOL 36 diuretic chlorthalidone 36 mg simvastatin 36 highest tertile 36 Circadian Clock 36 mg QD 36 Echocardiographic 36 wheals 36 Oral Fingolimod 36 dosing cohort 36 Dyspnea 36 Androgen Deprivation Therapy 36 Chemotherapeutic Agents 36 baseline serum creatinine 36 Sexual Encounter 36 Concomitant 36 Wechsler Memory 36 serum estradiol 36 Clinical Remission 36 zonisamide SR 36 serum HCV RNA 36 BENICAR HCT 36 underwent liver transplantation 36 hormone receptor status 36 mitomycin C 36 polyarticular 36 dimensional sonography 36 Neuropsychiatric Inventory 36 NIS LL 36 ovariectomized rats 36 weekly subcutaneous injections 36 treatment naive genotype 36 oral prednisolone 35 Female Orgasm 35 Genetic Variations 35 randomized Phase 2b 35 Differentially 35 CANCIDAS 35 EGFR HER2 35 Mini Mental 35 tacrolimus ointment 35 Gender Roles 35 CIMZIA R 35 ATV RTV 35 histologically confirmed 35 quetiapine risperidone 35 demographic variables 35 NYHA functional class 35 headaches backaches 35 randomized multicenter trial 35 guanfacine extended release 35 GH deficiency 35 Suicidal ideation 35 platelet dysfunction 35 5 HT2A 35 CK # plasma concentrations 35 uninfected infants 35 noncardiac chest pain 35 olanzapine LAI 35 lipid lowering medications 35 nocturnal awakenings 35 nontreated 35 logistic regressions 35 Evaluable 35 diplopia 35 Excretion 35 diarrhea flatulence 35 -#.# ± [002] 35 severe exacerbations 35 mechanically ventilated 35 dosed intravenously 35 posterior cingulate 35 Histologic 35 Long Term Outcomes 35 virological response 35 Juvenile Idiopathic Arthritis 35 Studied 35 Helicobacter pylori eradication 35 ovariectomized 35 cranial irradiation 35 unresectable HCC 35 elevated LDH 35 PsA 35 depression irritability 35 WOMAC 35 dose dose escalation 35 IRLS score 35 Hepatitis C Antiviral 35 polysomnography PSG 35 pegylated interferon alfa 2b 35 Deviance 35 hyperarousal 35 physiologic parameters 35 BENCHMRK 35 Chronic Pelvic Pain 35 RCTs 35 Exacerbations 35 mm Hg diastolic 35 comorbidities 35 Renal Failure 35 Score IPSS 35 Randomised 35 Nicotine Addiction 35 patients evaluable 35 Multiple Myeloma Patients 35 Cmax 35 URTI 35 mg dose 35 Hippocampal 35 NHANES #-# 35 pharmacodynamic 35 Paclitaxel Carboplatin 35 Antecedents 35 Mental Disorders DSM IV 35 Severely Obese 35 Pathologic 35 prucalopride 35 logistic regression models 35 placebo controlled clinical trials 35 HUMIRA adalimumab 35 urinary sodium excretion 35 rFSH 35 Kaplan Meier method 35 Febrile 35 Eligible 35 Lower Limb 35 Charlson Comorbidity Index 35 APTIVUS 35 subcutaneous injections 35 fatigue asthenia 35 p ≤ 35 RLAI 35 Candidates 35 Offenders 35 liver transplant recipients 35 Active Ulcerative Colitis 35 ACTEMRA TM 35 retrograde ejaculation 35 somnolence sleepiness 35 ziprasidone 35 Decompensated Heart Failure 35 hematologic toxicities 35 plus OBT 35 headache nausea dizziness 35 perioperatively 35 zolmitriptan 35 multicenter multinational 35 prospective longitudinal 35 Functions 35 #mg BID [001] 35 Desvenlafaxine Succinate 35 Partial Response 35 Initiated Phase 35 nutlin 3a 35 GI motility 35 Edinburgh Postnatal Depression 35 triptan therapy 35 interpersonal psychotherapy 35 Relapsing Remitting Multiple Sclerosis 35 PON1 activity 35 psychiatric morbidity 35 Beneficial Effects 35 GH deficient 35 methylprednisolone 35 docetaxel prednisone 35 Poster Presentations 35 emotional lability 35 obesity sedentary lifestyle 35 generalized anxiety disorder GAD 35 mcg albinterferon alfa 2b 35 Antiepileptic Drug 35 fosbretabulin 35 MARINOL ® 35 nonadherent 35 aromatase inhibitor therapy 35 Questionnaire 35 #q# deletion syndrome 35 double blinded randomized 35 placebo PBO 35 APTIVUS ritonavir 35 prostate carcinoma 35 urinary cadmium 35 Recipients 35 venlafaxine ER 35 Sex Hormones 35 selective cyclooxygenase 2 35 adenocarcinoma histology 35 Cardiorespiratory 35 Brain Atrophy